MDA/ALS Newsmagazine Vol. 14, No. 3

March 2009

Cover Story

Schemes and scams target people with ALS
In September 2006, Charlene DeMarco, a former doctor of osteopathy, and Elizabeth Lerner were convicted of 11 federal charges of trying to cheat people with ALS and their families. The two had claimed they could treat ALS patients with stem cell therapy, going so far as to say DeMarco had received...

Features

Investigators are looking for an ALS-specific “profile” in blood and spinal-fluid samples. When investigators coordinated by James Connor at Pennsylvania State University College of Medicine in Hershey compared spinal fluid samples from 41 people with ALS to samples from 33 people with othe...
The Eyegaze Communication system from LC Technologies enables people with ALS to use their eyes to generate speech, create Word documents, surf the Web, send emails, control their environment and stay on the job. Currently, LC Technologies offers two options — the Eyegaze Edge basic system ($8,700)...
David N. Gresh Entering sweepstakes via the Internet is a “lifeline to sanity” for David N. Gresh of Honeoye Falls, N.Y. Gresh, 55, received an ALS diagnosis in 2002, and two years later retired from his career as a kitchen and bathroom designer for a small design company called Bright Idea...
Catherine Lomen-Hoerth says some abnormal behaviors in people with ALS may be reaction to the disease; others may be something more. Jean-Pierre Julien says immunization strategies may prove beneficial in some cases of familial ALS. Induced pluripotent stem cells (iPS) hold promise b...
Sean Scott Sean Scott, president of the MDA-supported ALS Therapy Development Institute (ALS TDI) in Cambridge, Mass., died on Feb. 9, after a relatively short battle with ALS, which also took the life of his mother. Scott, 39, came to the ALS TDI as a volunteer in 2000 and quickly took the...

Research Roundup

ALS TDI and Asklepios collaborating on gene therapy development The MDA-supported ALS Therapy Development Institute (ALS TDI) in Cambridge, Mass., and Asklepios BioPharmaceutical in Chapel Hill, N.C., which also receives MDA support, are working together to develop viral delivery vehicles (vectors...

Advertisements

myMuscleTeam